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Epidemiological study of school performance and asthma medications 
among asthmatic Egyptian school children  
 
INTRODUCTION 
It is estimated that as many as 300 million people of 
all ages, and all ethnic backgrounds, suffer from 
asthma and the burden of this disease to 
governments, health care systems, families, and 
patients is increasing worldwide. The rate of asthma 
increases as communities adopt western lifestyles 
and become urbanised. With the projected increase 
in the proportion of the world's population that is 
urban from 45% to 59% in 2025, there will likely 
be a marked increase in the number of asthmatics 
worldwide over the next two decades. It is 
estimated that there may be an additional 100 
million persons with asthma by 2025. 1   
It is estimated that asthma accounts for about 1 
in every 250 deaths worldwide. Many of the deaths 
are preventable, being due to suboptimal long-term 
Original article 
Background: Childhood asthma is a major health problem in Egypt and 
worldwide. Barriers to reducing the burden of asthma include symptom-
based rather than disease-based approaches, tendency of care to be 
‘‘acute’’ rather than “regular” and cultural attitudes towards drugs and 
drug delivery systems. 
Objective: To measure the disease effect on school performance and to map 
asthma medications with respect to types, routes and course of use.  
Methods: This cross sectional study involved 206 Cairene asthmatic school 
children, enrolled from the school students’ health insurance facility of El-
Matareya Teaching Hospital and the pediatric outpatient clinic of Saint 
Mark Charity Hospital representing different social classes and residential 
locations. Their ages ranged between 5 and 15 years and they comprised 
100 males and 106 females. They were assessed clinically and by peak 
expiratory flowmetry. Parents or caregivers were interviewed about disease 
symptoms, school achievement and attendance and medications used 
including relievers and controllers, route and course of use, whether 
continuously, intermittently and/or during attacks.  
Results: Asthma had a strong impact on school achievement and school 
absence; 77.3% of study population reported school absence due to asthma 
and 41.3% reported weak to average school achievement. School 
performance was associated with asthma severity; the majority of moderate 
asthmatics (64.6%) had average and weak school performance.  Number of 
days of school absence demonstrated highly significant relation with asthma 
severity; 43.6% of moderate asthmatics had 5-6 absent days/month and 
33.4% had 3-4 absent days/month. Combined β2-agonists and xanthines was 
the most commonly used (54.8%) reliever therapy followed by β2-agonists 
alone (44.2%) while corticosteroids were the most common controllers used 
(97.6%). Therapy was taken mainly by oral than inhalation route. Other 
medications like cromolyns, anti-histamines, anti-leukotrienes and anti-
cholinergics were rarely used. Both rectal and injection routes were rarely 
used also.  
Conclusion: Asthma has a social burden on asthmatic children as it affects 
both school achievement and school attendance. Medical management of 
asthma in Egyptian children still lags behind available medical knowledge. 
Patients’ and health care givers’ education is a cornerstone in improving 
the current status of asthma management in Egypt.       
 
Keywords: asthma medications; asthma severity; children; school 
performance. 
Mohamed A. 
Tageldin,  
Gamal S. Aly*, Salah 
Mostafa*, Hany 
Khalil**. 
 
 
From the Chest 
Department, *Medical 
Section of Institute of 
Postgraduate Childhood 
Studies, Ain Shams 
University, **Saint 
Mark Charity Hospital, 
Cairo, Egypt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence:  
Dr. Hany Khalil, Saint 
Mark Charity Hospital, 
Cairo, Egypt. 
E-mail:Khalil_hany@ 
yahoo.com 
Tageldin  et al. 
24 
medical care and delay in obtaining help during 
deadly exacerbations.  
Asthma is being increasingly diagnosed among 
Egyptian children. Of major concern is a 10% 
annual increase in mortality.2 It is a common cause 
of emergency room visits and hospital admissions. 
It was estimated that up to one in four Egyptian 
children with asthma is unable to attend school 
regularly because of poor asthma control.3 
Barriers to reducing the burden of asthma 
include generic barriers like poverty, poor disease 
education, and poor health services, infrastructure 
and environmental barriers like indoor and outdoor 
air pollution, tobacco smoking, and occupational 
exposures. Moreover, symptom-based rather than 
disease-based approaches to the management of 
asthma and tendency of care to be ‘‘acute’’ rather 
than “regular” are significant barriers. Patient 
barriers include; lack of information, under-use of 
self-management, over-reliance on acute care and 
cultural attitudes towards drugs and drug delivery 
systems like for example steroids and inhalers1.   
We, therefore, sought to measure the disease effect 
on school achievement and school absence and to 
map the asthma medication types, routes of 
administration and course of therapy to estimate the 
patients' compliance and adherence to the standard 
regimen of therapy. 
 
METHODS 
 
Subjects and study design 
The study included 206 asthmatic children who 
matched the inclusion criteria: age between 5 to 15 
years, asthma diagnosed since ≥ 1 year and absence 
of chronic illnesses other than atopic diseases like 
nasal and or skin allergy. The majority of cases 
were enrolled from asthmatic school children 
covered by school students health insurance at El-
Matareya Teaching Hospital (Cairo, North and East 
regions), and the Saint Mark Charity Hospital 
pediatric outpatient clinic (Cairo North and City 
Center regions) between January 2004 and January 
2005. An informed consent was obtained from the 
parents or caregivers prior to enrollment and the 
study protocol was approved by the ethics 
committee of the Institute of Postgraduate 
Childhood Studies. 
 
Clinical examination 
Asthma severity was classified as mild intermittent, 
mild persistent, moderate persistent, or severe 
persistent, based on the criteria proposed by the 
Egyptian Guidelines for Asthma Management. 4 
 
Peak flowmetry 
Peak expiratory flow rate (PEFR), was measured 
for every patient and used as a co-factor to 
determine asthma severity. Proper instructions on 
how to perform the forced expiratory maneuver 
were given to patients and the highest values of two 
or three recordings were taken. 5 
 
Questionnaire 
Parents or caregivers as well as older children were 
asked about their disease using a comprehensive 
detailed questionnaire. Asthma severity was 
classified by symptoms frequency, nighttime 
symptoms and limitation of physical activity. 
School achievement and school absence were 
assessed in relation to disease exacerbation and/or 
severity. 
Participants were asked to list any medications 
they receive including relievers e.g. β2-agonist, 
xanthines, or anti-cholinergics and/or controllers 
e.g. corticosteroids, leukotriene modifiers, or anti-
histamines, defining the type, route of 
administration e.g. inhalation, oral, rectal, injection, 
or combined. The course of therapy; whether 
continuous, or intermittent was recorded.  
 
Statistical Methods 
Data were analyzed via a statistical software 
package (SPSS; Statistical Package for Social 
Sciences, Inc, Chicago, Ill version 12). Frequency 
distribution of variables was performed for asthma 
severity, school achievement, school absence, and 
medication types, routes and course of 
administration in order to measure the weight of 
each variable. Chi-square testing was performed to 
evaluate the relation among these data. Multi-level 
frequency analysis was performed between asthma 
severity grades and details of therapy modalities 
including type, route and course of administration. 
Quantitative variable analysis for age and PEFR 
was done exploring the mean, median and standard 
deviation. For all tests, p values less than 0.05 were 
considered statistically significant.  
 
RESULTS 
The subjects recruited into the study were living in 
El-Matareya (n=66), El-Wayli (n=29), Ain Shams 
(n=26), Mostorod (n=24), El-Amireya (n=21), 
Ezbet El Nakhl (n=18), El-Marg (n=12) and other 
residential areas (n=10) of Cairo.  
The majority of the study population (82.7%) 
presented with wheezy chest and diminished PEFR 
for expected (mean = 150.9 L/min), while 17.3% 
were enrolled during disease quiescence. About one 
half of the studied sample had intermittent asthma 
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(50.5%) while the rest had either mild (26.2%) or 
moderate (23.3%) persistent asthma. More than a 
quarter (27.3%) of children reported limitation of 
physical activity due to asthma (table 1). 
School achievement and school absence 
strongly correlated with asthma; 77.3% of study 
population reported school absence due to asthma 
and 41.3% reported weak and average school 
achievement (5.3% and 36% respectively), (figure 
1). 
In addition, school performance was 
significantly associated with asthma severity; the 
majority of moderate asthmatics (64.6%) had 
average and weak school performance (14.6% and 
50% respectively), (figure 2). 
Numbers of days of school absence were 
significantly associated with asthma severity; 
43.6% of children with moderate asthma had 
average absence of 5-6 days/month and 33.4% had 
3-4 absent days/month (figure 3). 
 
Table 1. Frequency analysis of asthma symptoms, 
physical signs and severity. 
Physical Activity Frequency Percent
      Not limited               149 72.7%
  Limited            56 27.3%
                   Total 205 100%
Chest examination
                     Normal 31 17.3%
                    Wheezy 148 82.7%
                      Total 179 100%
Asthma Severity
Mild Intermittent 104 50.5%
Mild Persistent 54 26.2%
Moderate Persistent 48 23.3%
Total 206 100%  
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Figure 1. Frequency analysis of school 
performance and school absence co-related with 
asthma. 
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Figure 2. School performance in association with 
asthma severity. 
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Figure 3. Numbers of days of school absence in 
association with asthma severity. 
 
The results revealed that combined β2-agonists 
and theophylline constituted the most common 
(54.8%) bronchodilators used in children with mild 
(90.7%) and moderate (95.8%) persistent asthma 
followed by β2-agonists alone (44.2%) especially in 
mild intermittent (80.8%) asthmatics. Other 
bronchodilators like anti-cholinergics (ipratropium 
bromide) were rarely used (table 2 & figure 4). 
The oral route was the predominant route of 
administration of bronchodilators (in 61.2% of 
studied patients). Inhalation therapy was used by 
26.6% of patients especially those with mild 
intermittent asthma (48.1%) (table 2 & figure 5).  
Concerning the course, continuous, intermittent 
and during attack uses were almost equally 
encountered. The course of administration of 
bronchodilators was significantly related to asthma 
severity.  
Multi-level frequency analysis revealed that the 
main form of therapy used continuously was 
combined oral β2-Agonists and xanthines (80%) 
whereas during attacks, inhalation therapy 
predominated (56%) especially with mild 
intermittent asthma (tables 3 & 4). 
In our series, controller therapy was 
predominantly corticosteroids (97.6%); other 
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medications like sodium cromoglycate, anti-
histamines and leukotriene receptor blockers were 
rarely used. Oral route was the main route (69.9%) 
followed by the inhalation route (26.2%) (table 2). 
There was a significant relation between the 
route of administration and asthma severity. The 
inhalation route was mainly used in mild 
intermittent asthma (48.1%) (figure 7). Also, the 
course of administration of controller therapy 
differed with grades of asthma severity.  
Continuous use was more prevalent in moderate 
persistent asthma (86.7%) while intermittent use 
dominated in mild persistent asthma (64.2%). In 
mild intermittent asthma, the controller therapy was 
used only during exacerbations (58%) (figure 8).  
Also multi-level frequency analysis revealed 
that oral corticosteroids as controllers dominated 
both the continuous (87%) and the intermittent use 
of controller therapy (71%). During attacks, inhaled 
corticosteroids was the main line of preventive 
therapy (54%) followed by oral corticosteroids 
(39%), (tables 5, 6 and 7).  
Our data suggested that there was an inadequate 
use of inhaled corticosteroids in the long-term 
treatment of asthma. Almost all the children had no 
written asthma action plan, nor did they have 
spacers to use for inhalation therapy.
 
Table 2. Frequency analysis of asthma medications (bronchodilators and controllers medications). 
Medications/types, routes & course 
 
Frequency 
 
Percent 
 
Bronchodilator 
Types 
Β2-Agonists alone 91 44.2% 
Theophylline alone 1 0.5% 
Ipratropium bromide alone 0 0% 
Β2-Agonists + Theophylline 113 54.8% 
Β2-Agonists + Theophylline + Ipratropium bromide 1 0.5% 
Route of administration 
Oral only 126 61.2% 
Inhaler only 55 26.6% 
Oral + Inhaler 20 9.7% 
Oral + Rectal 3 1.5% 
Oral + Injection 2 1.0% 
Course of therapy 
Continuous 65 32.7% 
Intermittent 74 37.2% 
During Attacks 59 29.6% 
Intermittent + During Attacks 1 0.5% 
Controller therapy 
Types 
Corticosteroids alone 201 97.6% 
Cromolyns alone 1 0.5% 
Anti-histamines alone 0 0% 
Anti-leukotrienes alone 0 0% 
Long Acting β2-Agonists alone 0 0% 
Corticosteroids + Anti-histamines 4 1.9% 
Route of administration 
Oral only 144 69.9% 
Inhaler only 54 26.2% 
Oral + Inhaler 8 3.9% 
Course of therapy 
Continuous 62 31.3% 
Intermittent 77 38.9% 
During Attacks 59 29.8% 
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P = 0.000 
Figure 4. Bronchodilator types in relation to asthma severity. 
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Figure 5. Routes of bronchodilator therapy in relation to asthma severity. 
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Figure 6. Course of bronchodilator therapy in relation to asthma severity. 
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Figure 7. Controller medication routes in relation to asthma severity 
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Figure 8. Course of controller medication in relation to asthma severity 
 
 
Table 3. Continuous use (n=65) of different routes of administration of bronchodilators in association 
with asthma severity*. 
Timing Route  
Asthma Severity 
Total Mild 
Intermittent 
Mild 
Persistent 
Moderate 
Persistent 
C
on
tin
uo
us
ly
 
Oral β2-Agonists 1(50)   1 (1.9) 
β2 & Xanth 1(50) 17(100) 34(100) 52(98.1) 
Total 2(100) 17(100) 34(100) 53(100) 
Inhaler β2-Agonists 2(100) 1(100)  3(100) 
Total 2(100) 1(100)  3(100) 
Inhaler & Oral β2-Agonists 1(50)   1(20) 
β2 & Xanth 1(50) 1(100) 2(100) 4(80) 
Total 2(100) 1(100) 2(100) 5(100) 
Oral & Rectal β2 & Xanth   2(100) 2(100) 
Total   2(100) 2(100) 
Oral & Injection β2 & Xanth   2(100) 2(100) 
Total   2(100) 2(100) 
* Values are given as count (%) 
Xanth = Xanthines. 
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Table 4. During attacks (n=59) use of different routes of administration of bronchodilators in 
association with asthma severity*. 
Timing Route  
Asthma Severity 
Total Mild 
Intermittent 
Mild 
Persistent 
Moderate 
Persistent 
D
ur
in
g 
A
tta
ck
s 
Oral β2-Agonists 18(81.8)   18(81.8) 
β2 & Xanth 4(18.2)   4(18.2) 
Total 22(100)   22(100) 
Inhaler β2-Agonists 33(100)   33(100) 
Total 33(100)   33(100) 
Inhaler & 
Oral 
β2-Agonists 3(75)   3(75) 
β2,Xanth&Ach 1(25)   1(25) 
Total 4(100)   4(100) 
During attacks 
& intermittent 
Oral & Rectal β2 & Xanth  1(100)  1(100) 
Total  1(100)  1(100) 
* Values are given as count (%) 
Xanth = Xanthines.  Ach = Anticholinergics 
 
Table 5. Continuous use (n=62) of different routes of administration of preventive therapy in relation 
to asthma severity*. 
Timing Route  
Asthma Severity 
Total Mild 
Intermittent 
Mild 
Persistent 
Moderate 
Persistent 
C
on
tin
uo
us
ly
 
Oral Steroids 2(100) 17(100) 35(94.6) 54(96.4) 
Steroids & 
A-hist 
  2(5.4) 2(3.6) 
Total 2(100) 17(100) 37(100) 56(100) 
Inhaler Steroids 2(100) 1(100)  3(100) 
Total 2(100) 1(100)  3(100) 
Inhaler & Oral Steroids 1(100)  2(100) 3(100) 
Total 1(100)  2(100) 3(100) 
* Values are given as count (%) 
A-hist = Antihistamines 
 
 
Table 6. Intermittent use (n=77) of different routes of administration of preventive therapy in relation 
to asthma severity*. 
Timing Route  
Asthma Severity 
Total Mild 
Intermittent 
Mild 
Persistent 
Moderate 
Persistent 
In
te
rm
itt
en
t 
Oral Steroids 21(100) 29(96.7) 5(100) 55(98.2) 
Steroids & 
A-hist 
 1(3.3)  1(1.8) 
Total 21(100) 30(100) 5(100) 56(100) 
Inhaler Steroids 15(93.8) 2(100) 1(100) 18(94.7) 
Cromolyns 1(6.2)   1(5.3) 
Total 16(100) 2(100) 1(100) 19(100) 
Inhaler & Oral Steroids  2(100)  2(100) 
Total  2(100)  2(100) 
* Values are given as count (%) 
A-hist = Antihistamines 
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Table 7. During attacks (n=59) use of different routes of administration of preventive therapy in 
relation to asthma severity*. 
Timing Route  
Asthma Severity 
Total Mild 
Intermittent 
Mild 
Persistent 
Moderate 
Persistent 
D
ur
in
g 
A
tta
ck
s 
Oral Steroids 23(100)   23(95.8) 
Steroids & 
A-hist 
 1(100)  1(4.2) 
Total 23(100) 1(100)  24(100) 
Inhaler Steroids 32(100)   32(100) 
Total 32(100)   32(100) 
Inhaler & Oral Steroids 3(100)   3(100) 
Total 3(100)   3(100) 
* Values are given as count (%) 
A-hist = Antihistamines 
 
 
DISCUSSION 
From the results of the current investigation it is 
observed that school achievement and school 
absence are strongly related to asthma severity. 
This comes in accordance with a relevant 
Egyptian study that revealed that at least one 
quarter of asthmatic (32/120) and epileptic children 
(10/42) were unable to attend school regularly 
because of their illness, compared with only 0.9% 
(1/113) and 3.2% (3/93) of diabetic and rheumatic 
children, respectively. Their results suggest that it is 
the specific nature of the disease that is the primary 
determinant of the severity of physical impact 
rather than the quality of delivered care.3 
School absenteeism is frequent due to 
insufficient control of asthma. This insufficient 
control is especially evident at schools where the 
usual risk factors of asthma are present. Allergenic 
risk with animal danders carried by other children, 
or school-acquired regular practice of sports, may 
be triggers for asthmatic child.6 
Regarding the bronchodilators used in our 
series, combined therapy with β2-agonists and 
theophylline were quite prevalent. Theophylline 
and oral β2-agonists seem to have an additive effect 
on the control of asthma.7 However; it remains 
unclear whether the combination has any clear 
clinical advantage compared to either drug used 
alone.  
The role of theophylline in the short and the 
long-term treatment of children with asthma is 
limited worldwide, but the low cost of this 
treatment may be behind its frequent use in some 
countries like Egypt. Theophylline is significantly 
more effective than placebo at controlling 
symptoms and improving lung function, even at 
doses below the normally recommended therapeutic 
range.8 
The oral route of bronchodilator administration 
in our series dominated followed by inhalation 
route, and this may reflect the prevalent use of 
theophylline. The inhalation route was mainly used 
in mild intermittent asthma due to the frequent use 
of rapid-acting inhaled β2-agonists known to be 
superior to other drugs in the treatment of acute 
episodes of wheeze.9 Other routes namely 
parenteral and rectal were rarely used. The onset of 
action of bronchodilators is substantially quicker 
when they are given via inhalation than when these 
drugs are administered orally.10 
Patients with moderate persistent asthma tended 
to use continuous bronchodilation whereas this was 
not the case with mild persistent asthmatics who 
were mainly administrating bronchodilators on 
intermittent basis. Standard asthma therapy holds 
that persistent asthma patients may be maintained 
on continuous long acting bronchodilator therapy. 
Rapid acting β2-agonists may be needed to provide 
quick relief that may last from 1-5 hours in 
children.11 
Many researchers agree that short-acting β2-
agonists provide significant protection against 
bronchoconstriction induced by various challenges; 
they have been the mainstay of asthma treatment in 
children for many years. These drugs are by far the 
most effective bronchodilators available and 
therefore the preferred treatment for acute asthma.9 
Corticosteroids were the main (97.6%) anti-
inflammatory treatment used comparably by 
asthmatics of different grades of severity included 
in this study. Other preventive medications like 
cromolyns, anti-histamines and anti-leukotrienes 
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were rarely used. Inhaled corticosteroids are the 
most effective controller therapy, and are therefore 
the recommended treatment for persistent asthma at 
any step of severity. Dose-response studies and 
dose titration studies in children12 demonstrate 
marked and rapid clinical improvements in 
symptoms and lung function at low doses of inhaled 
corticosteroids (e.g., 100 µg budesonide daily).13   
Emphasis should be made that the predominant 
route of corticosteroid intake was the oral route 
whether this was as continuous or as intermittent 
courses. This was the case with persistent asthma 
patients. This represents a deviation from the 
recommended protocols of corticosteroid therapy 
provided by the guidelines at hand. An important 
reason behind this is perhaps that many of the 
patients comply better with oral therapy. Oral 
intake should be limited to acute exacerbations 
whether viral induced or otherwise.14 
 In the absence of spacers, many patients do not 
get the desired effect with inhalation therapy. The 
cost of inhalation versus oral therapy is another 
issue that can not be overlooked. 
As noticed in the results of this study, most of 
the patients with moderate severity (87%) were 
maintained on continuous courses of oral 
corticosteroids. This raises much concern on the 
impact of this practice on their growth. Hence it 
becomes a necessity to provide patients with an 
action plan. 
Worth mentioning is that most of the study 
population have school health insurance coverage 
which is limited only to certain medications such as 
β2-agonists (tablets, syrup, inhalers) and xanthines 
(tablets, syrup). Oral corticosteroids (tablets, syrup) 
and anti-histamines (tablets, syrup) were also 
among the available controller medications.  
More broadly, our findings regarding medication 
usage coupled with the prevalence of children with 
mild and moderate persistent asthma and the 
frequency of respiratory symptoms suggest that this 
population was being treated in a way that is not in-
line with both local and international asthma 
guidelines. Compounding the problem of 
inadequate medication is the observed low usage of 
asthma action plans or peak flow meters, which are 
both part of recommended patient education and 
self-management activities. These shortfalls could 
be related to inadequate quality of care, limitations 
in access to and continuity of care, communication 
gulfs between caregivers and providers, or other 
factors, and further investigation is needed to 
determine the root causes of this management gap. 
It is deduced that the cost and availability of 
medications represent important barriers to 
effective management in a number of low- and 
middle-income families, even those covered by 
health insurance authorities and organizations. 
Other patient’s barriers include; cultural factors, 
lack of information, underuse of self-management, 
over-reliance on acute care and use of alternative 
unproven therapies. 
Programs based on locally adapted asthma 
management guidelines have been shown to result 
in marked changes in prescribing patterns, and 
reductions in morbidity and mortality from asthma. 
Also patient and patient’s family  education is very 
important to provide them with suitable information 
and training so that patient can keep well and adjust 
treatment according to a medication plan developed 
in advance with the health care professional. The 
emphasis must be on the development of an 
ongoing partnership among health care 
professionals, the patient, and the patient’s family. 
In conclusion, asthma has a social burden on 
asthmatic children as it affects both school 
achievement and school attendance. Still there is a 
gap between available medical knowledge and 
medical therapy and its utilization for the benefit of 
the asthmatic population. Under-treatment of 
asthma is a common problem. In particular, there is 
an inadequate use of inhalation therapy among 
Egyptians children; probably due to ignorance 
towards the proper use of this kind of therapy and 
the unexplained phobia from its side effects among 
the public. 
Wrong attitudes towards corticosteroid therapy 
prevail and there is a strong need to spread proper 
information on its use among health care providers 
and patients. 
 
ACKNOWLEDGEMENT 
The authors thank Dr. Refaat Iskander, Chest 
Consultant at El- Matareya Teaching Hospital, for 
his sincere effort and help during the course of the 
study. 
 
REFERENCES 
1. Masoli M, Fabian D, Holt S, Beasley R; Global 
Initiative for Asthma (GINA) Program. The global 
burden of asthma: executive summary of the GINA 
Dissemination Committee report. Allergy 2004; 
59:469-78. 
2. Egyptian guidelines for asthmatic child by the   
Egyptian Paediatric Association, Cairo; 1999. 
Tageldin et al. 
32 
3. Bassili A, Zaki A, Zaher SR, El-Sawy IH, Ahmed 
MH, Omar M, et al. Quality of care of children 
with chronic diseases in Alexandria, Egypt: the 
models of asthma, type 1 diabetes, epilepsy, and 
rheumatic heart disease. Egyptian-Italian 
Collaborative Group on Pediatric Chronic Diseases. 
Pediatrics 2000; 106(1): E12. 
4. Egyptian guidelines for asthma management by the   
Egyptian society of chest diseases and tuberculosis, 
Cairo; 1999. 
5. Sly RM. Pediatric Allergy. New Hyde Park, NY, 
Medical Examination Publishing Company, 1985. 
6. Karila C, Luc C, Dubus JC. The asthmatic child 
at school: difficulties encountered and proposed 
solutions. Arch Pediatr. 2004 Jun; 11 Suppl 2:120s-
123s. 
7. Chow OK, Fung KP. Slow-release terbutaline and 
theophylline for the long-term therapy of children 
with asthma: a Latin square and factorial study of 
drug effects and interactions. Pediatrics 1989; 
84:119-25. 
8. Bierman CW, Pierson WE, Shapiro GG, 
Furukawa CT. Is a uniform round-the-clock 
theophylline blood level necessary for optimal 
asthma therapy in the adolescent patient? Am J Med 
1988; 85:17-20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. Pedersen S. Treatment of acute 
bronchoconstriction in children with use of a tube 
spacer aerosol and a dry powder inhaler. Allergy 
1985; 40:300-4. 
10. Shaw RJ, Waller JF, Hetzel MR, Clark TJ. Do 
oral and inhaled terbutaline have different effects on 
the lung? Br J Dis Chest 1982; 76:171-6. 
11. Formgren H. Clinical comparison of inhaled 
terbutaline and orciprenaline in asthmatic patients. 
Scand J Respir Dis 1970; 51:203-11. 
12. Shapiro G, Bronsky EA, LaForce CF, 
Mendelson L, Pearlman D, Schwartz RH, et 
al. Dose-related efficacy of budesonide 
administered via a dry powder inhaler in the 
treatment of children with moderate to severe 
persistent asthma. J Pediatr 1998; 132:976-82. 
13. Pedersen S, O'Byrne P. A comparison of the 
efficacy and safety of inhaled corticosteroids in 
asthma. Allergy 1997; 52:1-34. 
14. Tal A, Levy N, Bearman JE. Methylprednisolone 
therapy for acute asthma in infants and toddlers: a 
controlled clinical trial. Pediatrics 1990; 86:350-6. 
